Search

Displaying results 141 - 150 of 9781 in total
  1. Drug

    OTL-203

    go.drugbank.com/drugs/DB18643
    Investigational

    OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.

    Synonyms: Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene
  2. Drug

    Sabestomig

    go.drugbank.com/drugs/DB19326
    Investigational

    Sabestomig is under investigation in clinical trial NCT05216835 (Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma).

    Synonyms: 3, TIM3, TIM-3, TIMD3, CD366)], humanized and Ho, Immunoglobulin G1-kappa/lambda, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279) and HAVCR2 (hepatitis A virus cellular receptor 2, T cell immunoglobulin and mucin domains family member
  3. Drug

    AB-201

    go.drugbank.com/drugs/DB18629
    Investigational

    [L48340] It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.

    Synonyms: Ex vivo expanded allogeneic cord blood-derived NK cells that have been genetically modified to express a HER2-directed CAR and secrete IL-15
  4. Drug

    OTL-102

    go.drugbank.com/drugs/DB18642
    Experimental

    OTL-102 consists of autologous CD34+ enriched cells that contain hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene.

    Synonyms: Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene
  5. Drug

    Butylidenephthalide

    go.drugbank.com/drugs/DB17259
    Experimental

    Synonyms: 3-butylidenephthalide, mixture of cis and trans isomers
  6. Drug

    Zifibancimig

    go.drugbank.com/drugs/DB19332
    Investigational

    Zifibancimig is under investigation in clinical trial NCT04567303, focusing on participants with neovascular age-related macular degeneration.

    Synonyms: Immunoglobulin G1 Fab fragment, bispecific, anti-(human vascular endothelial growth factor A and angiopoietin 2) (human monoclonal RO7250284 γ1-chain), disulfide with human monoclonal RO7250284 κ-chain, mmunoglobulin Fab G1-kappa, anti-[Homo sapiens ANGPT2 (angiopoietin 2, Ang2)] and anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF), monoclonal antibody, bispecific, biparatope
  7. Drug

    Azercabtagene zapreleucel

    go.drugbank.com/drugs/DB17185
    Investigational

    Synonyms: Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome., Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati
  8. Drug

    Ergidina

    go.drugbank.com/drugs/DB18565
    Experimental

    Ergidina is a recombinant human minibody against complement component C5 fused with RGD-motif.

    Synonyms: Neutralizing scFv dimer to C5 fused at the C terminal end to the Fc domains of human IgG1 and the cyclic RGD-4C peptide (ACDCRGDCFCG)
  9. Drug

    NGN-401

    go.drugbank.com/drugs/DB18594
    Investigational

    NGN-401 is a recombinant serotype 9 adeno-associated virus (AAV) encoding an intron encoding a miRNA generating sequence, complementary miRNA binding sites and a full-length human methyl cytosine binding

    Synonyms: Recombinant serotype 9 adeno-associated virus (AAV) encoding an intron encoding a miRNA generating sequence, complementary miRNA binding sites and a full-length human methyl cytosine binding protein 2
  10. Drug

    NKX101

    go.drugbank.com/drugs/DB18131
    Investigational

    NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.

    Synonyms: a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15